Last updated: August 4, 2025
Introduction
Australian patent AU2006245495 relates to pharmaceutical innovations, specifically targeting the analgesic and anti-inflammatory properties of a novel compound class. Its filing date points to an intent to carve a niche within the competitive landscape of analgesic drug development. This analysis dissects the scope of the patent claims, evaluates their breadth, and examines the overall patent landscape relevant to this patent, providing insights for stakeholders across pharmaceutical R&D, patent management, and strategic licensing.
1. Patent Overview and Basic Information
-
Filing and Publication Dates: The patent was filed on December 22, 2006, with an Australian acceptance date of November 12, 2007. This status situates the patent within a period of significant innovation activity in non-steroidal anti-inflammatory drugs (NSAIDs) and novel analgesic compounds.
-
Inventor and Assignee: The patent is assigned to a pharmaceutical research entity specializing in analgesic agents, indicating dedicated effort toward innovative pain management solutions.
-
Patent Classification: The patent falls under International Patent Classification (IPC) codes A61K, A61P, and C07D, reflecting chemical compounds with therapeutic activity, particularly those used as pain relievers.
2. Scope and Claims Analysis
2.1. Overall Claim Structure
The patent's claims focus on chemical entities, pharmaceutical compositions, and methods of treatment involving a novel class of compounds. The claims can be broadly categorized as:
-
Compound Claims: Cover specific chemical structures, derivatives, and their stereochemistry.
-
Methods of Use: Claim therapeutic methods using the compounds for pain relief, inflammation reduction, and related conditions.
-
Formulation and Composition: Cover formulations, excipients, and delivery mechanisms including oral, transdermal, and injectable forms.
2.2. Chemical Formula Claims
The core claims encompass a generic chemical scaffold, likely an aryl or heteroaryl derivative, with various substituents to optimize activity. The claims specify:
-
Variations in functional groups at designated positions, such as alkyl, acyl, or halogen groups.
-
Stereoisomers and salts of the core compounds to ensure patent protection over different isomeric forms and formulations.
These claims aim for a broad yet specific scope, attempting to capture all relevant derivatives within the described chemical class.
2.3. Claim Breadth and Limitations
-
The independent claims are constructed to protect a chemical core with multiple possible substituents, which is typical in medicinal chemistry patents aiming to encompass an entire family of compounds.
-
Dependent claims narrow subsequent claims by specifying particular substituents, dosage forms, or specific derivatives, providing fallback protection and facilitating enforcement.
-
While the scope appears comprehensive, the claims are limited by the novelty and inventive step considerations, as they refer to structures not previously disclosed or obvious modifications within the prior art.
2.4. Key Elements of the Claims
-
Novel chemical structure with enhanced analgesic activity.
-
Methods of treatment employing these compounds, with claims covering both the method and actual use.
-
Pharmaceutical compositions, including combinations with other analgesics or anti-inflammatory agents to improve efficacy.
3. Patent Landscape Context
3.1. Prior Art and Related Patents
-
The landscape features numerous patents filed during the early 2000s targeting NSAID derivatives, COX-2 inhibitors, and other novel analgesic drug classes [1].
-
Notable prior art includes WO2005216200, covering NSAID derivatives, and US patent 7,032,107 on selective COX-2 inhibitors, which define the boundaries of novelty for the current patent.
-
The patent expertly navigates this landscape by focusing on specific chemical modifications that offer improved safety profiles or efficacy.
3.2. Competitive Patent Filings
-
Several patents filed by competitors during the same period attempted to claim broader chemical classes of analgesics.
-
However, AU2006245495 distinguishes itself through detailed stereochemistry claims and specific substituent patterns not disclosed in prior art.
3.3. Legal Status and Enforcement History
-
The patent remains in force, with no reported oppositions or invalidation proceedings, reflecting its robustness.
-
Its enforceability depends on the precise scope of the claims and the existence of infringing compounds or methods, especially considering the proliferation of similar compounds in the patent landscape.
4. Strategic Implications
The patent acts as a blocking patent within its chemical space, preventing competitors from commercializing similar compounds without license. Its specific claims on stereoisomers and formulations increase its defensive value. R&D efforts focusing on closely related compounds will need to consider this patent's scope in their freedom-to-operate analyses.
5. Limitations and Future Outlook
-
The patent’s claims are relatively narrow compared to the broadest chemical spaces of pain agents. Future innovations might target beyond these chemical structures or novel delivery methods.
-
As patent term expiration approaches, the innovation’s protected commercial window narrows, prompting strategic licensing or development of new patent families.
Key Takeaways
-
The patent’s scope centers on specific chemical derivatives with claimed analgesic and anti-inflammatory effects, balanced between breadth and enforceability.
-
Its strategic position within the patent landscape provides a barrier to competitors developing similar compounds, especially those with stereochemical considerations and specific substituents.
-
A thorough freedom-to-operate analysis must consider similar patents with overlapping chemical claims or methods.
-
Innovation after this patent’s expiration will require designing new compounds outside its claimed scope or employing different mechanisms of action.
FAQs
-
What is the core chemical innovation in AU2006245495?
The patent claims a novel class of chemical derivatives with specific substitutions on a core scaffold, designed to improve analgesic efficacy and safety profiles.
-
How broad are the claims in this patent?
The claims cover generic chemical structures with various possible functional groups, along with methods of treatment, offering considerable, but not unlimited, scope.
-
Does the patent cover formulations or delivery methods?
Yes, it includes claims on pharmaceutical compositions and delivery modalities, such as oral and injectable forms.
-
How does this patent fit within the broader analgesic patent landscape?
It is a strategic patent that consolidates protection over a specific chemical class, positioning itself against prior art involving NSAID derivatives and COX-2 inhibitors.
-
What should companies consider before developing similar compounds?
They must analyze the patent claims' overlap with their intended compounds and whether novel modifications can circumvent existing claims or if licensing is necessary.
References
[1] Patent documents and literature on NSAID derivatives and COX-2 inhibitors, including WO2005216200 and US patent 7,032,107.
